Institutional shares held 159 Million
136K calls
4.8K puts
Total value of holdings $247M
$210K calls
$7K puts
Market Cap $323M
208,150,000 Shares Out.
Institutional ownership 76.44%
# of Institutions 141


Latest Institutional Activity in PGEN

Top Purchases

Q1 2025
Apella Capital, LLC Shares Held: 29K ($44.9K)
Q1 2025
Envestnet Asset Management Inc Shares Held: 43.9K ($68.1K)
Q1 2025
Gf Fund Management Co. Ltd. Shares Held: 7.26K ($11.3K)
Q1 2025
Janney Montgomery Scott LLC Shares Held: 31.5K ($48.8K)
Q1 2025
Mirae Asset Global Investments Co., Ltd. Shares Held: 9.8K ($15.2K)

Top Sells

Q1 2025
Exchange Traded Concepts, LLC Shares Held: 71.6K ($111K)
Q1 2025
Cambridge Investment Research Advisors, Inc. Shares Held: 192K ($297K)
Q1 2025
Sg Americas Securities, LLC Shares Held: 45.3K ($70.3K)
Q1 2025
Aaron Wealth Advisors LLC Shares Held: 11.1K ($17.3K)
Q1 2025
Allspring Global Investments Holdings, LLC Shares Held: 11.1K ($17.3K)

About PGEN

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.


Insider Transactions at PGEN

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
40.9M Shares
From 24 Insiders
Grant, award, or other acquisition 1.47M shares
Exercise of conversion of derivative security 699K shares
Other acquisition or disposition 15.1M shares
Open market or private purchase 23.6M shares
Sell / Disposition
19.8M Shares
From 5 Insiders
Payment of exercise price or tax liability 364K shares
Other acquisition or disposition 19.4M shares

Track Institutional and Insider Activities on PGEN

Follow PRECIGEN, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PGEN shares.

Notify only if

Insider Trading

Get notified when an Precigen, Inc. insider buys or sells PGEN shares.

Notify only if

News

Receive news related to PRECIGEN, INC.

Track Activities on PGEN